Bayer and its subsidiary Asklepios BioPharmaceutical (AskBio) have reported that the Phase Ib clinical trial of gene therapy AB-1005 to treat Parkinson’s disease (PD) met the primary endpoint.

The results were reported after the companies concluded the 18-month data collection from the trial.

Sponsored by AskBio subsidiary Brain Neurotherapy Bio, the multi-site, multi-centre, non-randomised, parallel assignment trial had 11 subjects who were given AB-1005 to the putamen through one-time bilateral convection-enhanced delivery.

The trial was designed to assess the potential clinical effect and safety of the gene therapy in people with various stages of PD.

Outcomes of the study at 18 months included the occurrence of treatment-emergent adverse events (TEAEs), motor and non-motor symptoms.

According to the findings, the trial met its primary goal of safety of the treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, AB-1005 offered through neurosurgical delivery mode was found to be well-tolerated by all subjects without any serious adverse events linked to the gene therapy reported.

AskBio plans to present 18-month trial data, including secondary endpoints, in the second quarter of this year.

The company also intends to commence a Phase II trial with subject screening anticipated to begin in the first half of this year.

AskBio Parkinson’s and MSA scientific chair Krystof Bankiewicz said: “We are encouraged by these early data, which show AB-1005 to be well tolerated in this study in patients with mild to moderate Parkinson’s disease.

“Although there is still much to learn about this early-stage investigational gene therapy, these first findings will inform our work in this space and have the potential to contribute to the clinical advancement of AB-1005 for the treatment of Parkinson’s disease.”

In November last year, AskBio randomised the first subject in its Phase I REGENERATE MSA-101 trial of AB-1005 (AAV2-GDNF), a gene therapy to treat multiple system atrophy-parkinsonian type (MSA-P).

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.